Pricing
  1. JP-listed companies
  2. PhoenixBio Co.,Ltd.
  3. Financials
  4. Revenue growth (%)

PhoenixBio Co.,Ltd.【JP:6190】

Market cap
¥1.8B
P/E ratio
16.8x
Phoenix Bio provides pharmaceutical testing services using PXB mice with human liver cells to help drug companies predict how medicines work in people.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRevenue growth (%) YoY (%)
Mar 31, 2025-10.1-47.30%
Mar 31, 2024-19.2-131.89%
Mar 31, 202360.3+96.45%
Mar 31, 202230.7-235.41%
Mar 31, 2021-22.7-437.50%
Mar 31, 20206.7-81.40%
Mar 31, 201936.1-235.98%
Mar 31, 2018-26.6-2839.18%
Mar 31, 20171-97.46%
Mar 31, 201638.1-261.84%
Mar 31, 2015-23.6-234.17%
Mar 31, 201417.6-25.28%
Mar 31, 201323.5

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)